DK155143C - Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet - Google Patents

Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Info

Publication number
DK155143C
DK155143C DK420385A DK420385A DK155143C DK 155143 C DK155143 C DK 155143C DK 420385 A DK420385 A DK 420385A DK 420385 A DK420385 A DK 420385A DK 155143 C DK155143 C DK 155143C
Authority
DK
Denmark
Prior art keywords
breast
pct
treatment
antioestrogent
boney
Prior art date
Application number
DK420385A
Other languages
English (en)
Other versions
DK155143B (da
DK420385D0 (da
DK420385A (da
Inventor
Pierre Mauvais-Jarvis
Frederique Kuttenn
Original Assignee
Mauvais Jarvis Pierre
Frederique Kuttenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre
Publication of DK420385D0 publication Critical patent/DK420385D0/da
Publication of DK420385A publication Critical patent/DK420385A/da
Publication of DK155143B publication Critical patent/DK155143B/da
Application granted granted Critical
Publication of DK155143C publication Critical patent/DK155143C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK420385A 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet DK155143C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8400927A FR2558373B1 (fr) 1984-01-20 1984-01-20 Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
FR8400927 1984-01-20
PCT/EP1984/000436 WO1985003228A1 (fr) 1984-01-20 1984-12-21 Medicament antioestrogene pour administration percutanee
EP8400436 1984-12-21

Publications (4)

Publication Number Publication Date
DK420385D0 DK420385D0 (da) 1985-09-17
DK420385A DK420385A (da) 1985-09-17
DK155143B DK155143B (da) 1989-02-20
DK155143C true DK155143C (da) 1989-07-03

Family

ID=9300348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK420385A DK155143C (da) 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Country Status (8)

Country Link
US (1) US4919937A (da)
EP (2) EP0151326B1 (da)
JP (1) JPH0667826B2 (da)
AT (1) ATE73334T1 (da)
DE (1) DE3485581D1 (da)
DK (1) DK155143C (da)
FR (1) FR2558373B1 (da)
WO (1) WO1985003228A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
IL93693A (en) * 1989-03-10 2000-01-31 Endorech Inc Pharmaceutical compositions for the treatment of estrogen sensitive diseases
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
DE59703511D1 (de) * 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
US20020086856A1 (en) 1998-03-18 2002-07-04 Alfred Schmidt Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
WO2003041654A2 (en) * 2001-11-14 2003-05-22 Sirbasku David A Anti-estrogen and immune modulator combinations for treating breast cancer
PL370889A1 (en) * 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
DE60305068T2 (de) * 2002-12-18 2007-01-11 Laboratoires Besins International Behandlung von mastalgie mit 4-hydroxy-tamoxifen
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004060322A2 (en) 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1941871B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005058297A1 (en) * 2003-12-15 2005-06-30 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
DE602005005986T2 (de) * 2004-03-22 2009-06-04 Laboratoires Besins International 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
SI2450041T1 (sl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
KR100850910B1 (ko) * 2006-12-22 2008-08-07 삼성전자주식회사 블루투스 디바이스를 연결하기 위한 장치 및 방법
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires

Also Published As

Publication number Publication date
ATE73334T1 (de) 1992-03-15
DK155143B (da) 1989-02-20
EP0151326B1 (fr) 1989-07-12
US4919937A (en) 1990-04-24
DE3485581D1 (de) 1992-04-16
EP0151326A1 (fr) 1985-08-14
FR2558373A1 (fr) 1985-07-26
FR2558373B1 (fr) 1987-07-03
DK420385D0 (da) 1985-09-17
JPS61500914A (ja) 1986-05-08
JPH0667826B2 (ja) 1994-08-31
EP0169214B1 (fr) 1992-03-11
DK420385A (da) 1985-09-17
EP0169214A1 (fr) 1986-01-29
WO1985003228A1 (fr) 1985-08-01

Similar Documents

Publication Publication Date Title
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69531457D1 (en) Sulfonamide
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
FR2441625A1 (fr) (d2-imidazolinyl-2 amino)-5 pyrimidines, procede pour les preparer, et medicaments qui en contiennent
HU9501953D0 (en) Pharmaceutically active pyridine derivatives and process for the preparation thereof
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
HUT74674A (en) Use of modafinil for preparing pharmaceutica compositions for the treatment of sleep apnoea and ventilation problems of central origin
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
JPS57122085A (en) Circulatory disease extirpenter and use
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE193651T1 (de) Therapeutisches system zur behandlung der psoriasis
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
BR8008818A (pt) Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
DK12388A (da) Sialosylcholesterol, fremgangsmaade til fremstilling af og neuropatimiddel omfattende samme
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus